Virtus ETF Advisers’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,080
| Closed | -$330K | – | 629 |
|
|
2024
Q4 | $330K | Sell |
3,080
-969
| -24% | -$110K | 0.13% | 230 |
|
|
2024
Q3 | $405K | Hold |
4,049
| – | – | 0.19% | 201 |
|
|
2024
Q2 | $341K | Sell |
4,049
-1,579
| -28% | -$126K | 0.17% | 203 |
|
|
2024
Q1 | $411K | Buy |
5,628
+810
| +17% | +$59.7K | 0.22% | 192 |
|
|
2023
Q4 | $344K | Buy |
4,818
+914
| +23% | +$53.9K | 0.22% | 192 |
|
|
2023
Q3 | $234K | Sell |
3,904
-501
| -11% | -$33K | 0.14% | 230 |
|
|
2023
Q2 | $318K | Sell |
4,405
-399
| -8% | -$29.9K | 0.19% | 187 |
|
|
2023
Q1 | $353K | Buy |
4,804
+83
| +2% | +$5.9K | 0.19% | 165 |
|
|
2022
Q4 | $315K | Sell |
4,721
-327
| -6% | -$21.3K | 0.16% | 244 |
|
|
2022
Q3 | $271K | Buy |
5,048
+74
| +1% | +$4.35K | 0.11% | 285 |
|
|
2022
Q2 | $277K | Buy |
4,974
+809
| +19% | +$45.9K | 0.1% | 273 |
|
|
2022
Q1 | $292K | Hold |
4,165
| – | – | 0.13% | 178 |
|
|
2021
Q4 | $401K | Sell |
4,165
-1,789
| -30% | -$165K | 0.15% | 147 |
|
|
2021
Q3 | $517K | Sell |
5,954
-549
| -8% | -$42.5K | 0.23% | 134 |
|
|
2021
Q2 | $532K | Sell |
6,503
-3,351
| -34% | -$279K | 0.22% | 130 |
|
|
2021
Q1 | $937K | Buy |
9,854
+270
| +3% | +$25.5K | 0.4% | 95 |
|
|
2020
Q4 | $595K | Buy |
9,584
+1,002
| +12% | +$57.1K | 0.25% | 117 |
|
|
2020
Q3 | $510K | Buy |
8,582
+722
| +9% | +$49.3K | 0.27% | 133 |
|
|
2020
Q2 | $548K | Sell |
7,860
-1,032
| -12% | -$65.4K | 0.26% | 136 |
|
|
2020
Q1 | $403K | Sell |
8,892
-750
| -8% | -$42.5K | 0.17% | 197 |
|
|
2019
Q4 | $627K | Sell |
9,642
-705
| -7% | -$47.1K | 0.1% | 179 |
|
|
2019
Q3 | $643K | Sell |
10,347
-1,733
| -14% | -$109K | 0.13% | 169 |
|
|
2019
Q2 | $860K | Buy |
12,080
+3,259
| +37% | +$240K | 0.18% | 165 |
|
|
2019
Q1 | $692K | Buy |
8,821
+1,893
| +27% | +$143K | 1.47% | 20 |
|
|
2018
Q4 | $586K | Buy |
6,928
+396
| +6% | +$42.2K | 0.1% | 50 |
|
|
2018
Q3 | $1.12M | Buy |
6,532
+441
| +7% | +$66.5K | 0.12% | 44 |
|
|
2018
Q2 | $787K | Sell |
6,091
-4,763
| -44% | -$531K | 0.7% | 37 |
|
|
2018
Q1 | $1.12M | Sell |
10,854
-625
| -5% | -$61.8K | 0.97% | 25 |
|
|
2017
Q4 | $981K | Sell |
11,479
-2,863
| -20% | -$248K | 1.23% | 24 |
|
|
2017
Q3 | $1.22M | Hold |
14,342
| – | – | 0.16% | 51 |
|
|
2017
Q2 | $1.09M | Sell |
14,342
-1,114
| -7% | -$77.9K | 0.16% | 54 |
|
|
2017
Q1 | $1.02M | Buy |
15,456
+1,487
| +11% | +$97.8K | 0.18% | 66 |
|
|
2016
Q4 | $885K | Buy |
13,969
+5,342
| +62% | +$337K | 0.26% | 73 |
|
|
2016
Q3 | $549K | Buy |
8,627
+1,085
| +14% | +$79.7K | 0.27% | 67 |
|
|
2016
Q2 | $561K | Sell |
7,542
-1,343
| -15% | -$99.7K | 0.42% | 34 |
|
|
2016
Q1 | $594K | Buy |
+8,885
| New | +$540K | 0.82% | 25 |
|
Other funds holding LGND
CAM
SIMG
CC
Virtus ETF Advisers's LGND Position: Q1 2025 in Review
Virtus ETF Advisers sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 3,080 shares — an estimated $330K sold.
Virtus ETF Advisers first reported a position in LGND in Q1 2016 and held it in 36 quarters. The position peaked at $1.22M in Q3 2017. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.
- Virtus ETF Advisers reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 3,080 Ligand Pharmaceuticals shares in Q1 2025, an estimated $330K.
- Virtus ETF Advisers first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 36 quarters.
- Virtus ETF Advisers's Ligand Pharmaceuticals position peaked at $1.22M in Q3 2017.
- 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.